spacer
home > ict > winter 2009 > chain reactions
PUBLICATIONS
International Clinical Trials

Chain Reactions

 

Management of cold chain clinical supplies presents sponsor companies with significant logistical challenges, especially considering the global nature of distribution to many less developed regions and emerging markets. When investigational products are shipped, supplies are subject to various factors which may influence the way in which temperature-controlled shipping systems may operate. These variables include a myriad of external temperature ranges, supply routes, transit time, and availability of stability data and people.

The nature of clinical trial shipments means that they are exposed to more risks than commercial shipments due to their urgency, diverse destinations, shipping methodologies or routes and variable shipment quantities. However, the goal still remains to ensure a consistent flow of material arriving at the site in a condition which is fit for its intended use.

When contemplating cold chain logistics, there are a number of elements to take into consideration:

  • Packaging for maintenance of temperature control – active and passive shipping systems
  • Use of monitoring devices
  • Courier selection and transit time
  • Planning for deviations

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Jonathan Calderwood is the Global Marketing Manager for Almac Clinical Services (Almac Group). He was educated in Queen’s University, gaining a BSc in Biochemistry, and he holds a Post Graduate Diploma in Computer Science and in Marketing, and is a member of the Chartered Institute of Marketing. Jonathan has extensive experience in clinical trial supply production and project management, as well as in the business development field.

spacer
Jonathan Calderwood
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita

MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.
More info >>

White Papers

Protein Therapeutics

Reading Scientific Services Ltd (RSSL)


More info >>

 
Industry Events

Multimodal 2019

18-20 June 2019, NEC, Birmingham, UK

Now in its twelfth year, Multimodal is the UK and Ireland’s premier freight transport, logistics and supply chain management event.  Shippers and cargo owners attend to improve their businesses; by finding ways of moving their products more efficiently and by meeting new suppliers. 
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement